Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Young D. Kwon, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Michael F. Bender, Mangaiarkarasi Asokan, Qingbo Liu, Krisha McKee, Bob C. Lin, Tracy Liu, Mark K. Louder, Reda Rawi, Mateo Reveiz, Andrew J. Schaub, Chen-Hsiang Shen, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola & Peter D. Kwong. (2023) Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain. mAbs 15:1.
Read now
Read now
Delphine Valente, Christine Mauriac, Thorsten Schmidt, Ingo Focken, Jochen Beninga, Brian Mackness, Huawei Qiu, Pascale Vicat, Abdullah Kandira, Katarina Radošević, Srini Rao, John Darbyshire & Mostafa Kabiri. (2020) Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models. mAbs 12:1.
Read now
Read now
Benjamin E. Low, Gregory J. Christianson, Emily Lowell, Wenning Qin & Michael V. Wiles. (2020) Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice. mAbs 12:1.
Read now
Read now
Bryan Smith, Andrea Kiessling, Rocio Lledo-Garcia, Kate L. Dixon, Louis Christodoulou, Matthew C. Catley, Paul Atherfold, Lena E. D’Hooghe, Helene Finney, Kevin Greenslade, Hanna Hailu, Lara Kevorkian, Daniel Lightwood, Christoph Meier, Rebecca Munro, Omar Qureshi, Kaushik Sarkar, Sophie P. Shaw, Roohi Tewari, Alison Turner, Kerry Tyson, Shauna West, Stevan Shaw & Frank R. Brennan. (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs 10:7, pages 1111-1130.
Read now
Read now
Di Zhang, Anthony A. Armstrong, Susan H. Tam, Stephen G. McCarthy, Jinquan Luo, Gary L. Gilliland & Mark L. Chiu. (2017) Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization. mAbs 9:7, pages 1129-1142.
Read now
Read now
Miroslav Dostalek, Thomayant Prueksaritanont & Robert F. Kelley. (2017) Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. mAbs 9:5, pages 756-766.
Read now
Read now
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey. Xenobiotica 47:3, pages 194-201.
Read now
Read now
Maria Myzithras, Tammy Bigwarfe, Hua Li, Erica Waltz, Jennifer Ahlberg, Craig Giragossian & Simon Roberts. (2016) Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics. mAbs 8:8, pages 1606-1611.
Read now
Read now
Lindsay B. Avery, Mengmeng Wang, Mania S. Kavosi, Alison Joyce, Jeffrey C. Kurz, Yao-Yun Fan, Martin E. Dowty, Minlei Zhang, Yiqun Zhang, Aili Cheng, Fei Hua, Hannah M. Jones, Hendrik Neubert, Robert J. Polzer & Denise M. O'Hara. (2016) Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. mAbs 8:6, pages 1064-1078.
Read now
Read now
Articles from other publishers (13)
Huijuan Tang, Adetunji P. Fayomi, Shoumei Bai, Navneet Gupta, Sandra Cascio, Dongli Yang & Ronald J. Buckanovich. (2023) Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy. Gynecologic Oncology 171, pages 49-58.
Crossref
Crossref
Kenta Haraya, Haruka Tsutsui, Yasunori Komori & Tatsuhiko Tachibana. (2022) Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. Pharmaceuticals 15:5, pages 508.
Crossref
Crossref
Lu Shan, Nydia Van Dyk, Nantaporn Haskins, Kimberly M. Cook, Kim L. Rosenthal, Ronit Mazor, Sonia Dragulin-Otto, Yu Jiang, Herren Wu, William F. Dall’Acqua, Martin J. Borrok, Melissa M. Damschroder & Vaheh Oganesyan. (2021) In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance. Communications Biology 4:1.
Crossref
Crossref
Miho Nagayasu & Kazuhisa Ozeki. (2021) Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice. Pharmaceutical Research 38:4, pages 583-592.
Crossref
Crossref
Genki Nakamura, Kazuhisa OzekiHiroaki TakesueMitsuyasu TaboKen-ichi Hosoya. (2021) Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model. Biological and Pharmaceutical Bulletin 44:3, pages 389-395.
Crossref
Crossref
Bruce A. Kerwin, Chelsey Bennett, Yan Brodsky, Rutilio Clark, J. Alaina Floyd, Alison Gillespie, Bryan T. Mayer, Megan McClure, Christine Siska, Michael S. Seaman, Kelly E. Seaton, Jeremy Shaver, Georgia D. Tomaras, Nicole L. Yates & Randal R. Ketchem. (2020) Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. Journal of Pharmaceutical Sciences 109:1, pages 233-246.
Crossref
Crossref
Natasha R. Catlin, Andrea Z. Mitchell, Michael J. Potchoiba, Denise M. O'Hara, Mengmeng Wang, Minlei Zhang, Gerhard F. Weinbauer & Christopher J. Bowman. (2019)
Placental transfer of
125
iodinated humanized immunoglobulin G2Δa in the cynomolgus monkey
. Birth Defects Research 112:1, pages 105-117.
Crossref
Crossref
Kenta Haraya, Tatsuhiko Tachibana & Tomoyuki Igawa. (2019) Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metabolism and Pharmacokinetics 34:1, pages 25-41.
Crossref
Crossref
Christoph Niederalt, Lars Kuepfer, Juri Solodenko, Thomas Eissing, Hans-Ulrich Siegmund, Michael Block, Stefan Willmann & Jörg Lippert. (2017) A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. Journal of Pharmacokinetics and Pharmacodynamics 45:2, pages 235-257.
Crossref
Crossref
Aamir Zuberi & Cathleen Lutz. (2017) Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?. ILAR Journal 57:2, pages 178-185.
Crossref
Crossref
Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Atsuhiko Maeda, Kazuhisa Ozeki, Junichi Nezu, Masaki Ishigai & Tomoyuki Igawa. (2016) PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody–antigen binding model. Drug Metabolism and Pharmacokinetics 31:2, pages 123-132.
Crossref
Crossref
E. Sally Ward, Siva Charan Devanaboyina & Raimund J. Ober. (2015) Targeting FcRn for the modulation of antibody dynamics. Molecular Immunology 67:2, pages 131-141.
Crossref
Crossref
Akiko Ishii-Watabe, Minoru Tada, Takuo Suzuki & Nana Kawasaki. (2015) Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies次世代抗体医薬品の非臨床評価. YAKUGAKU ZASSHI 135:7, pages 857-866.
Crossref
Crossref